What question did this study set out to answer?

Evaluate the clinical utility, therapeutic roles, and ongoing limitations of left ventricular assist devices (LVADs) as bridges to transplantation, definitive therapy, or myocardial recovery.

August 1, 1999European Journal of Heart FailureOpen Access

Left Ventricular Assist Devices — Reasons to be Enthusiastic

View Full Paper

Ask AI

Bookmark

Authors

MDMario C. Deng TTTonny D.T. Tjan BABoulos Asfour

Discussion

Member takes

Overview

Review demonstrates clinical benefits of mechanical circulatory support in advanced heart failure, highlighting expanding roles as destination therapy and bridge to recovery.

Key Points

Evaluate the clinical utility, therapeutic roles, and ongoing limitations of left ventricular assist devices (LVADs) as bridges to transplantation, definitive therapy, or myocardial recovery.
Synthesized findings from clinical cohorts and multicenter registries evaluating paracorporeal and implantable mechanical circulatory support systems, including Novacor and TCI HeartMate.
Assessed outcomes across multiple clinical roles: bridge to transplantation, bridge to recovery via reverse remodeling, high-risk surgical backup, and permanent destination therapy.
Up to 74% of patients receiving mechanical circulatory support successfully undergo cardiac transplantation, with wearable devices markedly enhancing ambulatory quality of life.
Long-term mechanical support is feasible for periods of at least 1 to 3 years in non-transplant candidates, while mechanical unloading facilitates reverse remodeling and functional weaning in select patients.
A 20% to 40% mortality rate persists prior to transplantation, predominantly caused by early postoperative systemic infection and coagulation disorders.

Cite This Study

Deng et al. (1999) studied this question.

synapsesocial.com/papers/6a93c1ca780b4d04c87c00ec https://doi.org/10.1016/s1388-9842(99)00035-5

View Full Paper

Ask AI

Bookmark

August 1, 1999European Journal of Heart FailureOpen Access

Left Ventricular Assist Devices — Reasons to be Enthusiastic

View Full Paper

Ask AI

Bookmark

Authors

MDMario C. Deng TTTonny D.T. Tjan BABoulos Asfour

Discussion

Member takes

Overview

Review demonstrates clinical benefits of mechanical circulatory support in advanced heart failure, highlighting expanding roles as destination therapy and bridge to recovery.

Key Points

Evaluate the clinical utility, therapeutic roles, and ongoing limitations of left ventricular assist devices (LVADs) as bridges to transplantation, definitive therapy, or myocardial recovery.
Synthesized findings from clinical cohorts and multicenter registries evaluating paracorporeal and implantable mechanical circulatory support systems, including Novacor and TCI HeartMate.
Assessed outcomes across multiple clinical roles: bridge to transplantation, bridge to recovery via reverse remodeling, high-risk surgical backup, and permanent destination therapy.
Up to 74% of patients receiving mechanical circulatory support successfully undergo cardiac transplantation, with wearable devices markedly enhancing ambulatory quality of life.
Long-term mechanical support is feasible for periods of at least 1 to 3 years in non-transplant candidates, while mechanical unloading facilitates reverse remodeling and functional weaning in select patients.
A 20% to 40% mortality rate persists prior to transplantation, predominantly caused by early postoperative systemic infection and coagulation disorders.

Cite This Study

Deng et al. (1999) studied this question.

synapsesocial.com/papers/6a93c1ca780b4d04c87c00ec https://doi.org/10.1016/s1388-9842(99)00035-5

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark